dc.contributor.author | Lam, Thomas B L | |
dc.contributor.author | MacLennan, Steven | |
dc.contributor.author | Willemse, Peter-Paul M. | |
dc.contributor.author | Mason, Malcolm D. | |
dc.contributor.author | Plass, Karin | |
dc.contributor.author | Shepherd, Robert | |
dc.date.accessioned | 2020-10-02T23:04:42Z | |
dc.date.available | 2020-10-02T23:04:42Z | |
dc.date.issued | 2019-12-01 | |
dc.identifier | 147241110 | |
dc.identifier | c4116266-2117-4b66-b11e-9ab4186003d5 | |
dc.identifier | 85072774547 | |
dc.identifier | 31587989 | |
dc.identifier | 000496915900015 | |
dc.identifier.citation | Lam , T B L , MacLennan , S , Willemse , P-P M , Mason , M D , Plass , K & Shepherd , R 2019 , ' EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study) ' , European Urology , vol. 76 , no. 6 , pp. 790-813 . https://doi.org/10.1016/j.eururo.2019.09.020 | en |
dc.identifier.issn | 0302-2838 | |
dc.identifier.other | ORCID: /0000-0002-2691-8421/work/63244102 | |
dc.identifier.other | Mendeley: 6fdf58bf-a8a4-3e7c-a8db-2b27b4acb928 | |
dc.identifier.uri | https://hdl.handle.net/2164/15196 | |
dc.description | The authors are grateful to the following individuals and organisations for the following contributions: R. Bryan Rumble, MSc for reviewing and commenting on the manuscript; American Society of Clinical Oncology (ASCO) for providing members who participated in the survey and consensus group meeting; IPSEN for providing an unrestricted educational grant; however IPSEN did not have any access to the study data nor did they have any control over the final manuscript; European Association of Urology (EAU) for providing an unrestricted educational grant; however the EAU did not have any access to the data nor did they have any control over the final manuscript. | en |
dc.format.extent | 24 | |
dc.format.extent | 328102 | |
dc.format.extent | 775970 | |
dc.language.iso | eng | |
dc.relation.ispartof | European Urology | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | Deferred treatment with curative intent | en |
dc.subject | Active surveillance and monitoring | en |
dc.subject | Localised prostate cancer | en |
dc.subject | Eligibility | en |
dc.subject | Follow-up | en |
dc.subject | Reclassification | en |
dc.subject | Outcome measures | en |
dc.subject | Consensus statements | en |
dc.subject | Delphi survey | en |
dc.subject | Consensus group meeting | en |
dc.subject | Clinical practice guidelines | en |
dc.subject | R Medicine | en |
dc.subject | Urology | en |
dc.subject.lcc | R | en |
dc.title | EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study) | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Academic Urology Unit | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | https://doi.org/10.1016/j.eururo.2019.09.020 | |
dc.date.embargoedUntil | 2020-10-03 | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85072774547&partnerID=8YFLogxK | en |
dc.identifier.vol | 76 | en |
dc.identifier.iss | 6 | en |